Fifteen publications did not mention any restrictions in their enrollment criteria; the other 15 publications evaluated subpopulations of the total HSCT-TMA population, including 4 that allowed treatment with eculizumab, 3 that selected according to the specific type of graft-versus-host disease (GVHD) prophylaxis used, 2 that reported neuroblastoma, 2 that detailed intestinal symptoms, and 1 each that reported engraftment status, treatment with plasma exchange, monitoring for von Willebrand factor levels, and T cell-depleted HSCT. This evidence concerns the gene VWF and graft versus host disease.